Skip to main content

Table 1 Baseline characteristics of the 256 patients with rheumatoid arthritis (RA)

From: Anti-type II collagen antibodies are associated with early radiographic destruction in rheumatoid arthritis

  All RA patients
(n= 256)
Anti-CII-negative RA patients
(n= 248)
Anti-CII positive (> 200 AU/ml) RA patients
(n= 8)
PMann Whitney/chi square
Age at inclusion (years) 56 56 68 NS (0.17)
Female (%: number/total number) 71.5
(183/256)
71.4
(177/248)
75.0 (6/8) NS (0.82)
Disease duration at inclusion (months) 5.0 5.0 4.5 NS (0.32)
RF-positive, (%; number positive/total number) 63.3
(162/256)
62.9 (158/248) 50.0 (4/8) NS (0.43)
Anti-CCP2- positive, (%;number positive/total number) 57.8
(148/256)
58.5
(145/248)
37.5
(3/8)
NS (0.24)
Anti-MCV- positive (2 patients missing) 70.9
(180/254)
71.1
(175/246)
62.5 (5/8) NS (0.60)
CRP (mg/l) 14 14 37 0.0026
ESR (mm/h) 22.0 21.5 40.5 0.0396
Physician's assessment of disease activity (0-4) 2 2 2 NS (0.28)
Number of swollen joints 9.0 9.0 8.5 NS (0.82)
Number of tender joints 7 7 8 NS (0.46)
DAS28 5.005 4.990 5.760 NS (0.08)
Global VAS 45 45 40 NS (0.93)
Pain VAS 45 45 35 NS (0.39)
HAQ 0.880 0.880 1.500 0.0303
Patients starting DMARD therapy at baseline (%) 83.6
(214/256)
83.5 (207/248) 87.5
(7/8)
NS (0.76)
  1. Results are presented as medians and percentages (ratios). Differences between anti-native human collagen type II (anti-CII)-negative and anti-CII-positive patients were analyzed using the Mann-Whitney U test; differences between proportions were analyzed using the Chi square test or Fisher's exact test as appropriate. Anti-CCP, anti-cyclic citrullinated peptide antibodies; Anti-MCV, antibodies against modified citrullinated vimentin; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; DAS28, 28-joint disease activity score; VAS, visual analogue scale; HAQ, health assessment questionnaire; DMARD, disease-modifying anti-rheumatic drug; NS, not significant.